Meeting Banner
Abstract #1110

Evaluating Feraheme as a Potential Contrast Agent for Clinical IRON FMRI

Joseph B. Mandeville1, Krishna Srihasam2, Wim Vanduffel1, Margaret S. Livingstone2

1Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United States; 2Department of Neurobiology, Harvard Medical School, Boston, MA, United States

Feraheme is a newly FDA-approved drug for treating chronic iron anemia in clinical populations. The approved iron dose of 510 mg falls within a weight-normalized range of 5-10 mg/kg for human subjects within the range 50-100 kg. To evaluate this drug as a potential contrast-enhancing agent for human clinical fMRI, we performed experiments in awake non-human primates at 3 Tesla to validate theoretical calculations. Results suggest that this agent could enhance the CNR ratio of clinical fMRI by factors of 5 and 2.5 and 1.5 at 3 Tesla, respectively.